216 related articles for article (PubMed ID: 37240999)
1. Pharmacogenetic Analysis Enables Optimization of Pain Therapy: A Case Report of Ineffective Oxycodone Therapy.
Wiss FM; Stäuble CK; Meyer Zu Schwabedissen HE; Allemann SS; Lampert ML
J Pers Med; 2023 May; 13(5):. PubMed ID: 37240999
[TBL] [Abstract][Full Text] [Related]
2. Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
Pednekar D; Russell J; Bardolia C; Thacker D; Amin NS
Sr Care Pharm; 2024 Apr; 39(4):137-142. PubMed ID: 38528335
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
5. Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions.
Jeiziner C; Stäuble CK; Lampert ML; Hersberger KE; Meyer Zu Schwabedissen HE
Pharmgenomics Pers Med; 2021; 14():279-286. PubMed ID: 33642872
[TBL] [Abstract][Full Text] [Related]
6. Hydromorphone for cancer pain.
Li Y; Ma J; Lu G; Dou Z; Knaggs R; Xia J; Zhao S; Dong S; Yang L
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD011108. PubMed ID: 34350974
[TBL] [Abstract][Full Text] [Related]
7. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.
Palangio M; Morris E; Doyle RT; Dornseif BE; Valente TJ
Clin Ther; 2002 Jan; 24(1):87-99. PubMed ID: 11833838
[TBL] [Abstract][Full Text] [Related]
8. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
[TBL] [Abstract][Full Text] [Related]
9. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
10. Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism.
Deodhar M; Turgeon J; Michaud V
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575542
[TBL] [Abstract][Full Text] [Related]
11. Prospective Randomized Study Using Pharmacogenetics to Customize Postoperative Pain Medication Following Hip and Knee Arthroplasty.
Hamilton WG; Gargiulo JM; Reynolds TR; Parks NL
J Arthroplasty; 2022 Jun; 37(6S):S76-S81. PubMed ID: 35279338
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
13. Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone.
Ali S; Yukseloglu A; Ross CJ; Rosychuk RJ; Drendel AL; Manaloor R; Johnson DW; Le May S; Carleton B
Pain Rep; 2023 Dec; 8(6):e1113. PubMed ID: 38027465
[TBL] [Abstract][Full Text] [Related]
14. [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Naito T; Kawakami J
Yakugaku Zasshi; 2015; 135(5):709-15. PubMed ID: 25948306
[TBL] [Abstract][Full Text] [Related]
15. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study.
Singla N; Pong A; Newman K;
Clin Ther; 2005 Jan; 27(1):45-57. PubMed ID: 15763605
[TBL] [Abstract][Full Text] [Related]
16. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
[TBL] [Abstract][Full Text] [Related]
18. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
